Centene Corporation (CNC) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is mixed-to-cautiously-constructive — the bar is achievable on Medicaid HBR, but the single biggest swing factor is whether the June Wakely risk adjustment data confirms a meaningful receivable for CNC’s higher-acuity Silver tier Marketplace membership, which management deliberately excluded from Q2 guidance.

Heading into the Q2 2026 print, the consensus bar looks manageable: adjusted EPS consensus of ~$1.13 is well below the Q1 2026 actual of $3.37, consistent with management’s guided step-down in earnings cadence (Q1 heavy, Q2 still profitable, Q3 near breakeven, Q4 loss). The most important catalyst is the June Wakely actuarial report on ACA risk adjustment — management embedded only a conservative ~3% Marketplace pre-tax margin in guidance (vs. original ~4% target), explicitly reserving upside pending this data; if confirmed, it could push Marketplace margins to 4%+ and drive a meaningful EPS beat. On Medicaid, the trajectory is constructive: three consecutive quarters of HBR improvement, with consensus at ~93.96% for Q2 vs. the Q1 actual of 93.1%, implying the Street expects seasonal step-up — any outperformance here would be additive. Estimate revisions have been essentially flat since the Q1 print (FY 2026 EPS consensus moved from $3.53 to $3.52), suggesting the Street is in a wait-and-see posture rather than chasing the Q1 beat. The stock has rallied ~29% since the Q1 earnings date vs. IHF +19% and SPY +4%, meaning some outperformance is already priced in, though the stock still trades at a significant discount to historical levels. The key wildcard is the June Wakely data: if it confirms the risk adjustment receivable thesis, both the Marketplace margin and full-year EPS guidance could move materially higher; if it disappoints, the stock’s recent re-rating could face a sharp reversal.

Bar: Consensus adjusted EPS of ~$1.13 for Q2 2026 is a low absolute bar given Q1’s $3.37 beat, but reflects the company’s own guided seasonal step-down. The Medicaid HBR consensus of ~93.96% implies the Street expects seasonal deterioration from Q1’s 93.1% — any print at or below ~93.7% would be a positive signal.

Guidance/Tone: Management raised FY 2026 adjusted EPS guidance to >$3.40 (from >$3.00) after Q1, but deliberately embedded a conservative Marketplace margin assumption pending June Wakely data. Tone is confident on Medicaid and Medicare execution, prudent on Marketplace. No post-Q1 guidance revisions have been issued.

Estimate Trajectory: Revisions have been essentially flat since the Q1 print — FY 2026 EPS consensus moved from $3.53 to $3.52, and Q2 EPS moved from $1.11 to $1.13. The lack of upward revision despite the Q1 beat reflects the Street’s caution around the Marketplace risk adjustment outcome, creating potential cushion if Wakely data is favorable.

Stock Setup: CNC has rallied ~29% since the Q1 earnings date (Apr 28) vs. IHF +19% and SPY +4%, outperforming meaningfully. The stock still trades at a discount to historical multiples following the July 2025 guidance withdrawal, so the re-rating has room to continue if execution holds. However, the near-term setup is more balanced given the run.

Wildcard: The June Wakely risk adjustment data is the single most important variable. Management has guided to a ~3% Marketplace pre-tax margin but stated the data supports a range wrapping around the original 4% target — and potentially higher. Confirmation would be a material positive catalyst; disappointment would force a downward revision to Marketplace guidance and likely pressure the stock.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar on Medicaid HBR (~93.96% vs. Q1 actual of 93.1%), but the bigger swing factor is the Marketplace Commercial HBR — where the June Wakely risk adjustment data could drive a meaningful beat or miss relative to the ~82.5% consensus estimate.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Sources: Visible Alpha Consensus and Actuals Data; CNC Q1 2026 Earnings Release and Transcript (April 28, 2026). All consensus figures are latest available as of July 27, 2026.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Adjusted EPS (Diluted Operating)

KPI 2: Consolidated HBR (Medical Loss Ratio)

Pattern: CNC has beaten adjusted EPS in 7 of the last 8 quarters, with the sole miss in Q2 2025 driven by the Marketplace morbidity shock; on HBR, the beat/miss record is more mixed (4 beats, 4 misses over 8 quarters), reflecting the inherent volatility in medical cost trends across segments. The recent Q1 2026 EPS beat of +51% was the largest in the trailing 8-quarter window.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised meaningfully at Q1 2026 earnings (April 28) — adjusted EPS floor lifted from >$3.00 to >$3.40 — with no post-earnings revisions since. The key open item is the Marketplace margin assumption, which management deliberately set conservatively at ~3% pending June Wakely data; if confirmed, this is the primary source of potential upside to current guidance.

Source: CNC Q1 2026 Earnings Release and Transcript (April 28, 2026); Visible Alpha Consensus Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been essentially flat since the Q1 print — FY 2026 EPS consensus moved only -$0.01 from the post-Q1 baseline, and Q2 EPS moved +$0.01 — indicating the Street is in a wait-and-see posture rather than chasing the Q1 beat. The gap between current guidance (>$3.40 floor) and consensus ($3.52) is modest, suggesting limited cushion if Marketplace risk adjustment disappoints.

The near-complete absence of estimate revision since the Q1 print reflects the Street’s deliberate wait-and-see posture on the June Wakely risk adjustment data. If the data confirms a meaningful receivable, the Street would likely revise FY 2026 EPS estimates upward toward the $3.80–$4.00 range implied by a 4%+ Marketplace margin scenario — a potential 8–14% upside to current consensus.

Source: Visible Alpha Consensus and Actuals Data (as-of date: May 3, 2026 for baseline; July 27, 2026 for current).

5. Stock Performance

Key Takeaway: CNC has rallied ~29% since the Q1 2026 earnings date (April 28, 2026) vs. IHF (healthcare ETF) +19% and SPY +4%, with the outperformance driven primarily by the Q1 EPS beat and guidance raise — a re-rating of the margin recovery story rather than multiple expansion, as the stock still trades at a significant discount to historical levels.

CNC vs. IHF (iShares U.S. Healthcare Providers ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (April 28, 2026). Source: Stock Price Data.

Performance Summary (April 28 – July 28, 2026): CNC +29.3% | IHF +19.0% | SPY +3.8%

The stock’s outperformance vs. the sector ETF (+10 pp) and the broader market (+25 pp) reflects a fundamental re-rating of the margin recovery narrative. The Q1 2026 print — with adjusted EPS of $3.37 vs. consensus of $2.23 (+51% beat) — was the primary catalyst, driving an immediate ~9% gap-up on April 29. The stock continued to grind higher through June as the sector broadly re-rated on improving Medicaid rate dynamics and favorable Medicare Advantage trends. A modest pullback in mid-July (from ~$68 to ~$64) coincided with ELV’s Q2 2026 earnings (July 15) and UNH’s Q2 2026 earnings (July 16), which highlighted continued Medicaid cost pressures and commercial trend headwinds — read-through concerns that weighed on the managed care sector broadly. The stock has partially recovered heading into the Q2 print.

Sector ETF: IHF (iShares U.S. Healthcare Providers ETF) was selected as the benchmark, as it tracks managed care and healthcare services companies — CNC’s direct peer sub-sector.

Source: Stock Price Data (Yahoo Finance).

6. Peer Commentaries — Q2 2026 Read-Through

Key Takeaway: Peers reporting Q2 2026 results (MOH July 23, ELV July 15, UNH July 16) collectively signal that Medicaid cost trends are stable-to-in-line with expectations and rate adequacy is improving, which is constructive for CNC’s Medicaid HBR; however, MOH’s Marketplace adverse selection miss and ELV’s cautious risk adjustment accrual posture are the most important read-throughs for CNC’s single biggest open item — the June Wakely risk adjustment outcome.

Molina Healthcare (MOH) — Q2 2026 Earnings (Reported July 23, 2026)

Medicaid: MOH reported a Q2 2026 Medicaid MCR of 92.7%, in line with expectations, with full-year Medicaid MCR guidance unchanged at 92.9%. Medical cost trend remained stable at 5% — the trend has “plateaued” and the 250 bps acuity shift observed in 2025 has not recurred in 2026. High-trend categories (behavioral health, professional office visits, inpatient) are expected to remain stable in H2. MOH views 2026 as a “trough year” for Medicaid margins and remains optimistic about the 2027 rate-setting process as state actuaries incorporate more recent cost experience. Rate updates received are consistent with 4% guidance, and the rate/trend imbalance appears to have stabilized.

CNC Read-Through: Constructive for CNC’s Medicaid HBR. Stable trend at 5% and no new acuity reset supports CNC’s mid-4% net trend assumption. MOH’s optimism on 2027 rate-setting aligns with CNC’s constructive state partnership commentary. The 300 bps market underfunding thesis (MOH’s estimate) reinforces CNC’s case for continued rate adequacy improvement.

Marketplace: MOH’s Q2 2026 Marketplace MCR was 88.9%, higher than expectations, driven by prior-year risk adjustment true-ups and unfavorable current-year member acuity mix. Excluding prior-year items, normalized MCR was 87.3%. MOH reduced full-year Marketplace guidance by $1.50/share (from +$0.75 to -$0.75 loss), citing $0.50 from prior-year items and $1.00 from lower current-year membership outlook. High-cost drug utilization without corresponding HCCs is creating a risk adjustment imbalance. MOH plans to reduce its 2027 Marketplace footprint by ~$1B.

CNC Read-Through: Mixed-to-cautious for CNC’s Marketplace risk adjustment thesis. MOH’s adverse selection experience and risk adjustment miss suggest the market-wide morbidity shift may be more severe than expected in some geographies. However, CNC’s situation differs: 75% of its Silver tier members were renewals (vs. MOH’s more adverse new-member mix), and CNC has already flagged higher Silver acuity as the basis for its expected receivable. The key question is whether the June Wakely data confirms CNC’s receivable thesis or reveals a broader market-wide adverse selection problem similar to MOH’s experience.

Work Requirements / Medicaid Policy: MOH expects Medicaid membership to decline 2–3% per year for three years (8–9% cumulative), with only a minor acuity shift. The CMS interim final rule on work requirements does not change MOH’s long-term view. MOH is well-positioned for early 2027 rate updates, with ~55% of premium receiving January 1 updates.

CNC Read-Through: Broadly consistent with CNC’s own commentary. CNC’s Nebraska work requirement test case (July 1, 2026) is the first real-world data point; MOH’s gradual decline assumption aligns with CNC’s “smaller, more focused population” framing.

Elevance Health (ELV) — Q2 2026 Earnings (Reported July 15, 2026)

Medicaid: ELV reported Q2 2026 results ahead of its outlook, with Medicaid performance supporting the full-year framework. Rate updates received during Q2 were higher than anticipated, and July 1 rate activity was “constructive” and “modestly favorable to expectations” — now in the upper end of the mid-single-digit percent range. ELV views 2026 as the trough year for Medicaid margin (full-year outlook: approximately -1.75%), with improvement expected over time as rates increasingly reflect cost experience and care management actions mature. Membership and acuity remain broadly aligned with assumptions; ELV is not seeing a new stepwise acuity reset. ELV recently agreed to exit the DC Medicaid market and expects to exit additional markets over the next 12–18 months where a path to sustainable performance is not seen.

CNC Read-Through: Constructive for CNC’s Medicaid HBR. ELV’s “no new stepwise acuity reset” commentary and favorable July 1 rate activity are positive signals for CNC’s Q2 Medicaid HBR. ELV’s market exits (DC and potentially others) could benefit CNC if it retains or gains membership in those markets. The upper-end mid-single-digit rate update aligns with CNC’s ~4.5% composite rate yield guidance.

Medical Cost Trends: ELV identified elevated cost drivers concentrated in behavioral health, specialty pharmacy, outpatient surgery, and ED utilization — consistent with CNC’s own trend commentary. ELV is not assuming a material improvement in Medicaid trend in H2. Commercial costs are “stubbornly high” with medical cost trends modestly above 11%, driven by the No Surprises Act IDR process (contributing ~100 bps of total cost) and provider coding intensity.

CNC Read-Through: Consistent with CNC’s own trend narrative. ELV’s NSA/IDR commentary reinforces CNC’s aggressive litigation posture against fraudulent providers. The behavioral health and specialty pharmacy pressure is a shared industry theme.

Marketplace/ACA: ELV’s individual ACA business is developing “broadly consistent with how it was priced and planned.” Member retention is modestly ahead of expectations; ELV now expects to end 2026 with at least 1 million individual ACA members. The final 2025 CMS risk adjustment results were favorable to ELV’s prior estimate, but ELV is “prudently reestablishing the majority of this prior year favorability” in its 2026 risk adjustment accrual given current market dynamics and maturing claims experience. The higher mix of bronze plans creates more pronounced seasonality; ELV is not extrapolating early-year favorability for 2027.

CNC Read-Through: Cautious for CNC’s Marketplace risk adjustment thesis. ELV’s decision to “prudently reestablish” prior-year risk adjustment favorability in its 2026 accrual — rather than flowing it through as upside — suggests the industry is taking a conservative posture on risk adjustment given maturing claims data. This is a potential headwind for CNC’s expectation of a meaningful risk adjustment receivable, though CNC’s Silver-heavy, renewal-dominated membership mix is a differentiating factor.

Medicare Advantage: ELV’s MA results were stronger than expected, supporting a path to at least 2% operating margin in 2026. Portfolio actions for 2026 are translating to improved performance. ELV remains confident in returning to at least 12% adjusted EPS growth in 2027 off a higher $26 earnings baseline.

CNC Read-Through: Positive for CNC’s Medicare segment. ELV’s MA outperformance and favorable trend commentary support CNC’s path to MA breakeven in 2027. The industry-wide MA improvement trend is a tailwind.

UnitedHealth Group (UNH) — Q2 2026 Earnings (Reported July 16, 2026)

Medicaid: UNH reported Q2 2026 Medicaid performance “in line with expectations.” Trend remains elevated vs. pre-pandemic levels but stable, with continued pressure in specialty pharmacy, home and community-based services, and behavioral health. UNH is beginning to see early signs of improvement from initiatives targeting elevated behavioral health cost trends. As of July 1, rate actions accounting for ~80% of annual revenue are within the expected forecast; annualized 2026 rate impacts are expected to be in the 6–7% range, still lagging elevated medical trend. Full-year 2026 Medicaid margins are projected within the previously communicated -1% to -1.7% range.

CNC Read-Through: Broadly neutral for CNC’s Medicaid HBR. UNH’s stable trend and in-line Q2 performance are consistent with CNC’s mid-4% net trend assumption. UNH’s 6–7% rate update (higher than CNC’s ~4.5% composite yield) reflects UNH’s different state mix and contract structure. The behavioral health early improvement signals are a positive read-through for CNC’s ABA trend stabilization thesis.

Medical Cost Trends: UNH sees divergence within its portfolio. Medicare medical cost trends are running below initial estimates (below the ~10% initial assumption), driven by UNH’s own initiatives (benefit design, care management, network curation) and a more favorable respiratory season. Commercial costs are “stubbornly high” at modestly above 11%, driven by the NSA IDR process (contributing ~100 bps of total cost, with 40% of IDR claims ineligible and 60% of arbitration cases brought by just 5 entities) and provider coding intensity. UNH notes the average IDR payout is now 11x Medicare rates, with some decisions at 30x.

CNC Read-Through: Positive for CNC’s Medicare segment. UNH’s Medicare trend coming in below expectations is a constructive read-through for CNC’s Medicare HBR. The NSA/IDR commentary reinforces CNC’s aggressive litigation posture and highlights the industry-wide nature of the problem.

Marketplace/ACA: UNH’s exchange business is performing “better than planning expectations,” but has no financial impact as UNH has pledged to return profits to consumers for 2026. This is separate from UNH’s commercial trend discussion.

CNC Read-Through: Limited direct read-through given UNH’s pledge to return ACA profits to consumers. However, UNH’s better-than-expected ACA performance suggests the market-wide morbidity environment may be more favorable than feared in some geographies — a modest positive for CNC’s risk adjustment receivable thesis.

Guidance Update: UNH raised full-year 2026 adjusted EPS guidance to $19.50–$20.00 (from prior guidance), with UnitedHealthCare operating earnings raised to at least $12B and Optum Health to at least $2.2B. Full-year MCR guidance is 88.1% +/- 25 bps. UNH expects to complete at least $5B in share repurchases in 2026 (vs. initial $2.5B guidance). The company maintains its 13–16% long-term EPS growth rate target.

CNC Read-Through: Positive sector sentiment. UNH’s guidance raise and strong capital return posture signal improving confidence in the managed care sector’s earnings trajectory, which is a positive backdrop for CNC’s own margin recovery story.

Peer Read-Through Summary Table

Sources: MOH Q2 2026 Earnings Call Transcript (July 23, 2026); ELV Q2 2026 Earnings Call Transcript (July 15, 2026); UNH Q2 2026 Earnings Call Transcript (July 16, 2026).

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the June Wakely risk adjustment data (now available to management), which will determine whether CNC raises its Marketplace margin assumption from the conservative ~3% embedded in guidance — this is the primary catalyst for the Q2 print and any guidance update.

• June 2026 — June Wakely Risk Adjustment Data (Key Catalyst): Management flagged the June Wakely actuarial report as the critical data point to confirm or deny the Marketplace risk adjustment receivable thesis. CNC embedded only a ~3% Marketplace pre-tax margin in Q1 guidance (vs. original ~4% target), explicitly reserving upside pending this data. If confirmed, management indicated the range of outcomes “wraps around the original 4% target and frankly, higher than that at the top end.” This is the single most important input for the Q2 print and any guidance revision.
• July 28, 2026 — Q2 2026 Earnings (Today): CNC reports Q2 2026 results before market open. Conference call at 8:30 AM ET. Key items to watch: (1) Medicaid HBR vs. consensus ~93.96%; (2) Marketplace risk adjustment update and any guidance revision; (3) FY 2026 EPS guidance update; (4) Nebraska work requirement early data.
• June 22, 2026 — Board Appointment (Lauren Tyler): CNC appointed Lauren Tyler to its Board of Directors, effective June 19, 2026. Tyler brings 30+ years of experience including senior roles at JPMorgan Chase (Global Head of HR for Asset & Wealth Management, Global Firmwide Chief Auditor, Global Head of Investor Relations). She will serve on the Audit Committee and Compensation and Talent Committee. Currently also serves on the boards of Cencora and Guardian Life.
• May 15, 2026 — Annual Shareholder Meeting: Shareholders elected directors, approved executive pay, and rejected an independent chairman proposal. No material governance changes.
• April 28, 2026 — Q1 2026 Earnings Beat & Guidance Raise: CNC reported adjusted EPS of $3.37 vs. consensus $2.23 (+51% beat), the largest beat in the trailing 8-quarter window. FY 2026 adjusted EPS guidance raised to >$3.40 from >$3.00. Premium & service revenue guidance raised by $1B (driven by Texas Medicaid). SG&A guidance lowered 10 bps. Investment income guidance raised $50M. Medicaid HBR improved 50 bps YoY (third consecutive quarter of improvement). Medicare segment outperformed in both MA and PDP. Marketplace came in on track on a pre-tax basis despite higher Silver tier HBR, with management flagging a meaningful risk adjustment receivable pending June Wakely data.
• April 2026 — Leadership Structure Evolution: Dan Finke joined as Group President overseeing Medicaid and Commercial businesses; Michael Carson elevated to Group President overseeing Medicare, PDP, and Specialty businesses. Framed as strengthening execution capability as margin recovery progresses.
• Q1 2026 — $1B Debt Reduction: CNC sold $1B of 2025 PDP risk-share receivables and used proceeds to repurchase $1B of senior notes due 2027. Debt-to-cap ratio improved to 43.2% from 46.5% at year-end 2025. Total debt stands at $16.4B with no revolving credit facility borrowings.
• July 1, 2026 — Nebraska Work Requirements Launch: Nebraska became the first state to implement Medicaid work requirements under the One Big Beautiful Bill Act, providing the first real-world test case. CNC has the largest Medicaid membership of any single managed care insurer (~12.4M members) and carries the most direct exposure to enrollment contraction. Management views the rollout as more data-driven and thoughtful than the post-PHE redeterminations.
• Sector — Peer Q2 2026 Earnings (July 15–23, 2026): ELV (July 15) and UNH (July 16) both raised FY 2026 guidance, signaling improving managed care sector fundamentals. MOH (July 23) raised Medicaid guidance but cut Marketplace guidance by $1.50/share due to adverse selection. The sector broadly re-rated positively on ELV/UNH results before a modest pullback on MOH’s Marketplace miss. See Section 6 for detailed read-through analysis.
• Ongoing — No Surprises Act / IDR Litigation: CNC has taken an aggressive litigious posture against fraudulent NSA/IDR exploitation, filing multimillion-dollar lawsuits against providers. UNH’s Q2 commentary (IDR payouts at 11x Medicare rates, 40% of claims ineligible) validates the industry-wide nature of the problem and CNC’s litigation strategy.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by executives since Q1 earnings — the only notable transaction is a discretionary open-market sale of 80,000 shares by Director Kenneth Burdick on June 10, 2026 (not on a 10b5-1 plan), which is worth monitoring but is not clustered with other insider selling. All other transactions are routine equity award grants (code A) or tax withholding (code F).

Assessment: The only transaction warranting attention is Director Kenneth Burdick’s discretionary open-market sale of 80,000 shares on June 10, 2026 — a meaningful size relative to his holdings and not on a 10b5-1 plan. However, this is an isolated transaction by a single director (not an executive officer), and there is no clustering of insider selling across the management team. The absence of any open-market buys by executives is notable given the stock’s ~29% rally since Q1 earnings, but is not unusual for a company in active margin recovery mode with limited excess cash at the holding company level ($437M at Q1 end). No 10b5-1 plan initiations were filed in the period.

Source: Insider Transaction Data (SEC Form 4 filings).